Cancer Treatment Sector Anticipates 30% Increase in Investment in Microbiome-Based Therapies by 2030, Driven by Research on Gut Microbiota's Role in Enhancing Chemotherapy and Immune Response.
CRSPEDITNTLAXBI
Statements (2)
- Bullish
Investors Will Likely Prioritize Clinical-stage Biotech Firms focusing on innovative cancer therapies over the next decade In Response To the abstract's findings on engineered probiotics that improve tumor-specific delivery of therapeutic agents, indicating a potential shift in treatment paradigms.
- Bullish
The Biotechnology Sector Will Likely See Increased Investment In companies developing engineered probiotics for tumor-targeted therapies in the coming years Due To the abstract's reported breakthrough in combining enzyme/prodrug chemotherapy with immunotherapy, promising enhanced efficacy in cancer treatment.